OCE’s role in cancer drug development, regulation, and patient advocacy since 2017 – FDA Oncology

FDA Oncology shared a post on X:

”Thank you to FDA Oncology Center of Excellence experts for the July 11 conversations on cancer discussion OCE’s role in cancer drug development, regulation, and patient advocacy since our inception in 2017 as part of the Biden Cancer Moonshot!”

Watch attached video.
Source: FDA Oncology/X

The Oncology Center of Excellence (OCE) was given authorization through the 21st Century Cures Act of 2016 and formally founded on January 19, 2017. This Center brings together specialists from across the FDA to facilitate accelerated evaluations of medical products intended for the treatment of oncologic and hematologic malignancies. The OCE also leads numerous initiatives aimed at advancing both the research and regulatory processes related to medical products for individuals affected by cancer.